StockNews.AI
LMAT
StockNews.AI
173 days

LeMaitre Q4 2024 Financial Results

1. LeMaitre reported Q4 2024 sales of $55.7 million, up 14%. 2. Gross margin improved to 69.3% due to better efficiency. 3. Quarterly dividend increased by 25% to $0.20 per share. 4. Management expects Q1 2025 sales growth of 8% to 10%. 5. Cash reserves increased to $299.7 million, enhancing strategic growth.

17m saved
Insight
Article

FAQ

Why Very Bullish?

LeMaitre's robust sales growth, margin expansion, and dividend increase suggest strong market confidence. Historical performance shows similar outcomes after positive earnings reports.

How important is it?

The financial results and outlook directly impact investor sentiment and stock performance. Strong revenue growth and a substantial cash position signal stability and potential for future growth.

Why Short Term?

Immediate effects of earnings and dividends typically influence stock prices quickly. Previous announcements of earnings and dividends have led to spikes in stock prices.

Related Companies

MDTSYKBSX
BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results Sales $55.7mm, +14% (+14% organic) vs. Q4 2023Gross margin 69.3%, +121 bpsOp. income $12.9mm, +26%Op. margin 23%Earnings per diluted share $0.49, +30%Cash up $175.8mm sequentially to $299.7mm Grafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin improved to 69.3% (vs. 68.1% in Q4 2023), due to higher ASPs and manufacturing efficiencies. Operating income of $12.9mm was up 26% in Q4. Operating expenses grew 12% largely due to sales-related compensation and personnel. The Company employed 152 (+12%) sales reps at 12/31/2024 and 31 (+29%) sales managers. Chairman/CEO George LeMaitre said, “2024 was a productive year. More reps, higher ASPs, a better GM and controlled spending produced growth in sales (+14%), op. income (+42%) & EPS (+44%). $300mm of cash provides strategic optionality.” Business Outlook  Q1 2025 GuidanceFull Year GuidanceSales$56.7mm - $58.7mm(Mid: $57.7mm, +8%, +10% Org.)$235.4mm - $242.8mm(Mid: $239.1mm, +9%, +10% Org.)Gross Margin69.7%69.7%Op. Income$12.3mm - $13.7mm(Mid: $13.0mm, +10%)$57.3mm - $62.4mm(Mid: $59.8mm, +15%)Op. Margin (Mid)23%25%EPS$0.48 - $0.53(Mid: $0.50, +15%)$2.15 - $2.32(Mid: $2.24, +16%)  Quarterly Dividend Increase On February 18, 2025, the Company's Board of Directors approved a quarterly dividend of $0.20/share (+25%) of common stock. The dividend will be paid on March 27, 2025, to stockholders of record on March 13, 2025. Convertible Senior Notes On December 19, 2024, the Company issued 2.50% Convertible Senior Notes due 2030 in the aggregate principal amount of $172.5mm. The notes will mature on February 1, 2030 unless earlier purchased, redeemed, or converted. Net proceeds of $167.7mm will be used for working capital, general corporate purposes and business development activities. For more information, see the Company’s December 16, 2024 press release. Share Repurchase Program On February 18, 2025, the Company's Board of Directors authorized the repurchase of up to $75.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 17, 2026, unless extended by the Board. Conference Call Reminder Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website. A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company. For more information about the Company, please visit www.lemaitre.com. Use of Non-GAAP Financial Measures LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release. In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events, including EBITDA. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and the aforementioned non-GAAP profitability measures to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that the presentation of guidance described above for sales, operating income and EPS provides an alternative and meaningful view of the Company’s profitability. Forward-Looking Statements The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, competition from other medical device companies and alternative medical technologies; our ability to source, acquire, and integrate acquisitions; our ability to increase the selling prices of our products; our ability to maintain historic levels of profit growth; our dependence on sole- or limited-source suppliers; our implementation of our new enterprise resource planning system; disruptions to our information technology systems or breaches of our information security systems; our ability to engage sales call points other than vascular surgeons; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the status of our regulatory approvals and compliance with regulatory requirements to market and sell our products both domestically and internationally; the occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other commercial matters; the occurrence of product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; and volatility in the price of our common stock; and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. CONTACT: Gregory MankerDirector of Business Development and Investor Relations781-362-1260 x 419gmanker@lemaitre.com LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)     CONDENSED CONSOLIDATED BALANCE SHEETS    (amounts in thousands)               December 31, 2024 December 31, 2023    (unaudited)   Assets            Current assets:      Cash and cash equivalents $25,610  $24,269   Short-term marketable securities  274,112   80,805   Accounts receivable, net  30,063   25,064   Inventory and other deferred costs  64,927   58,080   Prepaid expenses and other current assets  7,480   6,380  Total current assets  402,192   194,598         Property and equipment, net  24,800   21,754  Right-of-use leased assets  16,768   18,027  Goodwill  65,945   65,945  Other intangibles, net  35,819   41,711  Deferred tax assets  1,425   1,003  Other assets  4,868   3,740         Total assets $551,817  $346,778                Liabilities and stockholders' equity            Current liabilities:      Accounts payable $1,761  $3,734   Accrued expenses  24,732   23,650   Acquisition-related obligations  1,433   24   Lease liabilities - short-term  2,681   2,471  Total current liabilities  30,607   29,879         Convertible senior notes, net  167,772   -  Lease liabilities - long-term  15,232   16,624  Deferred tax liabilities  85   107  Other long-term liabilities  831   2,268  Total liabilities  214,527   48,878         Stockholders' equity      Common stock  242   239   Additional paid-in capital  213,760   200,755   Retained earnings  145,090   115,430   Accumulated other comprehensive loss  (6,184)  (4,625)  Treasury stock  (15,618)  (13,899) Total stockholders' equity  337,290   297,900         Total liabilities and stockholders' equity $551,817  $346,778          LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)      CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS    (amounts in thousands, except per share amounts)       (unaudited)                  For the three months ended For the year ended  December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023         Net sales$55,717  $48,883 $219,863  $193,484 Cost of sales 17,127   15,618  68,962   66,435          Gross profit 38,590   33,265  150,901   127,049          Operating expenses:        Sales and marketing 12,626   10,268  46,737   41,054  General and administrative 9,492   8,440  36,258   31,832  Research and development 3,618   4,351  15,650   16,966  Restructuring -   -  -   485 Total operating expenses 25,736   23,059  98,645   90,337          Income from operations 12,854   10,206  52,256   36,712          Other income (expense), net        Interest income 1,610   992  4,949   3,077  Interest expense (205)  -  (205)  -  Other income (loss), net (238)  115  (125)  (314)         Income before income taxes 14,021   11,313  56,875   39,475          Provision for income taxes 2,837   2,848  12,837   9,370          Net income$11,184  $8,465 $44,038  $30,105          Earnings per share of common stock        Basic$0.50  $0.38 $1.96  $1.36  Diluted$0.49  $0.38 $1.93  $1.34          Weighted - average shares outstanding:        Basic 22,506   22,278  22,452   22,217  Diluted 22,902   22,459  22,779   22,423                   Cash dividends declared per common share$0.16  $0.14 $0.64  $0.56                            LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)            SELECTED NET SALES INFORMATION              (amounts in thousands)               (unaudited)                                  For the three months ended For the year ended  December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023  $ % $ % $ % $ %Net Sales by Geography                Americas$36,629 66% $32,812 67% $144,583 66% $130,308 67% Europe, Middle East and Africa 15,275 27%  12,920 26%  59,969 27%  51,099 27% Asia Pacific 3,813 7%  3,151 7%  15,311 7%  12,077 6%Total Net Sales$55,717 100% $48,883 100% $219,863 100% $193,484 100%                              LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)         NON-GAAP FINANCIAL MEASURES         (amounts in thousands)         (unaudited)                         For the three months ended For the year ended     December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Reconciliation between GAAP and Non-GAAP EBITDA          Net income as reported $11,184  $8,465  $44,038  $30,105   Interest (income) expense, net  (1,405)  (992)  (4,744)  (3,077)  Amortization and depreciation expense  2,416   2,443   9,608   9,515   Provision for income taxes  2,837   2,848   12,837   9,370               EBITDA $15,032  $12,764  $61,739  $45,913               EBITDA percentage increase (decrease)    18%    34%                           LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)       NON-GAAP FINANCIAL MEASURES       (amounts in thousands)       (unaudited)                 Reconciliation between GAAP and Non-GAAP sales growth:        For the three months ended December 31, 2024         Net sales as reported $55,717       Impact of currency exchange rate fluctuations  95       Adjusted net sales   $55,812              For the three months ended December 31, 2023         Net sales as reported $48,883       Adjusted net sales   $48,883               Adjusted net sales increase for the three months ended December 31, 2024 $6,929 14%                     Reconciliation between GAAP and Non-GAAP projected sales growth:        For the three months ending March 31, 2025         Net sales per guidance (midpoint) $57,741       Impact of currency exchange rate fluctuations  954       Adjusted projected net sales   $58,695              For the three months ended March 31, 2024         Net sales as reported $53,478       Adjusted net sales   $53,478               Adjusted projected net sales increase for the three months ending March 31, 2025 $5,217 10%                     Reconciliation between GAAP and Non-GAAP projected sales growth:        For the year ending December 31, 2025         Net sales per guidance (midpoint) $239,111       Impact of currency exchange rate fluctuations  2,652       Adjusted projected net sales   $241,763              For the year ended December 31, 2024         Net sales as reported $219,863       Adjusted net sales   $219,863               Adjusted projected net sales increase for the year ending December 31, 2025 $21,900 10%           

Related News